Kristin S. Price

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC

Gonzalo Recondo, Magda Bahcall, Liam F. Spurr et al. · Clinical Cancer Research · 2020 · 210 citations

A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor

Ibiayi Dagogo‐Jack, Philicia Moonsamy, Justin F. Gainor et al. · Journal of Thoracic Oncology · 2021 · 62 citations · Full text

Oncology, Medicine, Cancer Management +9

Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers

Yoshihisa Kobayashi, Chhayheng Chhoeu, Jiaqi Li et al. · Nature · 2022 · 61 citations

Tumor Biology, Somatic Variant, Silent Mutations +6

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance <i>EGFR</i> Mutations

Jacqueline H. Starrett, Alexis Guernet, Maria Emanuela Cuomo et al. · Cancer Research · 2020 · 57 citations · Full text

Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma

Kyrillus S. Shohdy, Dario Martin Villamar, Yen Cao et al. · British Journal of Cancer · 2022 · 38 citations · Full text

Urology, Serial Ctdna Analysis, Genitourinary Cancer +9